Cargando…

Apolipoprotein A-I Mimetic Peptides Prevent Atherosclerosis Development and Reduce Plaque Inflammation in a Murine Model of Diabetes

OBJECTIVE: To determine the effect of the apolipoprotein A-I (ApoA-I) mimetic peptide, D-4F, on atherosclerosis development in a pre-existing diabetic condition. RESEARCH DESIGN AND METHODS: We induced hyperglycemia in 6-week-old apoE(−/−) female mice using streptozotocin. Half of the diabetic apoE(...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morgantini, Cecilia, Imaizumi, Satoshi, Grijalva, Victor, Navab, Mohamad, Fogelman, Alan M., Reddy, Srinivasa T.
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2010
Materias:	Pharmacology and Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2992786/ https://www.ncbi.nlm.nih.gov/pubmed/20826564 http://dx.doi.org/10.2337/db10-0844

Ejemplares similares

Anti-inflammatory and Antioxidant Properties of HDLs Are Impaired in Type 2 Diabetes
por: Morgantini, Cecilia, et al.
Publicado: (2011)

Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis
por: Woo, Jennifer MP, et al.
Publicado: (2010)

Apolipoprotein Mimetic Peptides: A New Approach for the Treatment of Asthma
por: Yao, Xianglan, et al.
Publicado: (2012)

Anti-tumorigenic and Platinum-Sensitizing Effects of Apolipoprotein A1 and Apolipoprotein A1 Mimetic Peptides in Ovarian Cancer
por: Marinho, Aline T., et al.
Publicado: (2019)

Apolipoprotein A-I and A-I mimetic peptides: a role in atherosclerosis
por: Getz, Godfrey S, et al.
Publicado: (2011)

Comparison of Mechanisms of Endothelial Cell Protections Between High-Density Lipoprotein and Apolipoprotein A-I Mimetic Peptide
por: Xu, Wenqi, et al.
Publicado: (2019)

Diabetes-Impaired Wound Healing Is Improved by Matrix Therapy With Heparan Sulfate Glycosaminoglycan Mimetic OTR4120 in Rats
por: Tong, Miao, et al.
Publicado: (2012)

Apolipoprotein A-I mimetic peptides (ApoAI MP) improve oxidative stress and inflammatory responses in Parkinson’s disease mice
por: Jiang, Hongfang, et al.
Publicado: (2022)

Treating the Intestine with Oral ApoA-I Mimetic Tg6F Reduces Tumor Burden in Mouse Models of Metastatic Lung Cancer
por: Chattopadhyay, Arnab, et al.
Publicado: (2018)

Apolipoprotein A-I Mimetic Peptide L-4F Suppresses Granulocytic-Myeloid-Derived Suppressor Cells in Mouse Pancreatic Cancer
por: Peng, Meiyu, et al.
Publicado: (2020)

Commentary: The apolipoprotein A-I mimetic peptide, D-4F, restrains neointimal formation through heme oxygenase-1 up-regulation
por: Li Volti, Giovanni, et al.
Publicado: (2017)

Oral Apolipoprotein A‐I Mimetic D‐4F Lowers HDL‐Inflammatory Index in High‐Risk Patients: A First‐in‐Human Multiple‐Dose, Randomized Controlled Trial
por: Dunbar, Richard L., et al.
Publicado: (2017)

Apolipoprotein E mimetic peptide CN-105 improves outcome in a murine model of SAH
por: Liu, Ji, et al.
Publicado: (2018)

Apolipoprotein Mimetic Peptides: An Emerging Therapy against Diabetic Inflammation and Dyslipidemia
por: Wolkowicz, Paul, et al.
Publicado: (2021)

Role of enterocyte Enpp2 and autotaxin in regulating lipopolysaccharide levels, systemic inflammation, and atherosclerosis
por: Chattopadhyay, Arnab, et al.
Publicado: (2023)

Chronic Administration of the Glucagon-Like Peptide-1 Analog, Liraglutide, Delays the Onset of Diabetes and Lowers Triglycerides in UCD-T2DM Rats
por: Cummings, Bethany P., et al.
Publicado: (2010)

The role of gut-derived oxidized lipids and bacterial lipopolysaccharide in systemic inflammation and atherosclerosis
por: Wang, Huan, et al.
Publicado: (2022)

Posing the rationale for synthetic lipoxin mimetics as an adjuvant treatment to gold standard atherosclerosis therapies
por: Millar, Braden, et al.
Publicado: (2023)

Apolipoprotein Mimetic Peptides: Potential New Therapies for Cardiovascular Diseases
por: Wolska, Anna, et al.
Publicado: (2021)

Collagen Mimetic Peptides Promote Corneal Epithelial Cell Regeneration
por: Baratta, Robert O., et al.
Publicado: (2021)

Optimization of a Glucagon-Like Peptide 1 Receptor Antagonist Antibody for Treatment of Hyperinsulinism
por: Peterson, Sean M., et al.
Publicado: (2023)

Comparative Effects of Prolonged and Intermittent Stimulation of the Glucagon-Like Peptide 1 Receptor on Gastric Emptying and Glycemia
por: Umapathysivam, Mahesh M., et al.
Publicado: (2014)

An Apolipoprotein A-I Mimetic Peptide Designed with a Reductionist Approach Stimulates Reverse Cholesterol Transport and Reduces Atherosclerosis in Mice
por: Ditiatkovski, Michael, et al.
Publicado: (2013)

ApoA-I mimetics reduce systemic and gut inflammation in chronic treated HIV
por: Daskou, Maria, et al.
Publicado: (2022)

Metabolic Syndrome Abolishes Glucagon-Like Peptide 1 Receptor Agonist Stimulation of SERCA in Coronary Smooth Muscle
por: Dineen, Stacey L., et al.
Publicado: (2015)

Apolipoprotein E mimetic peptide protects against diffuse brain injury
por: Zhao, Yaning, et al.
Publicado: (2014)

Transient Receptor Potential Vanilloid 1 Activation Enhances Gut Glucagon-Like Peptide-1 Secretion and Improves Glucose Homeostasis
por: Wang, Peijian, et al.
Publicado: (2012)

Inhibition of Dipeptidyl Peptidase-4 by Vildagliptin During Glucagon-Like Peptide 1 Infusion Increases Liver Glucose Uptake in the Conscious Dog
por: Edgerton, Dale S., et al.
Publicado: (2009)

The Apolipoprotein-AI Mimetic Peptide L4F at a Modest Dose Does Not Attenuate Weight Gain, Inflammation, or Atherosclerosis in LDLR-Null Mice
por: Averill, Michelle M., et al.
Publicado: (2014)

HDL as a Biomarker, Potential Therapeutic Target, and Therapy
por: Navab, Mohamad, et al.
Publicado: (2009)

Oxidized phospholipids cause changes in jejunum mucus that induce dysbiosis and systemic inflammation
por: Mukherjee, Pallavi, et al.
Publicado: (2021)

Advanced targeted nanomedicines for vulnerable atherosclerosis plaque imaging and their potential clinical implications
por: Li, Xue, et al.
Publicado: (2022)

Restoring the Extracellular Matrix: A Neuroprotective Role for Collagen Mimetic Peptides in Experimental Glaucoma
por: McGrady, Nolan R., et al.
Publicado: (2021)

The apolipoprotein A-I mimetic peptide, ETC-642, reduces chronic vascular inflammation in the rabbit
por: Di Bartolo, Belinda A, et al.
Publicado: (2011)

Apolipoprotein E mimetic peptide, CN‐105, improves outcomes in ischemic stroke
por: Tu, Tian Ming, et al.
Publicado: (2017)

An In Vitro Evaluation of the Antibacterial Efficacy of Solanum xanthocarpum Extracts on Bacteria From Dental Plaque Biofilm
por: Arumuganainar, Deepavalli, et al.
Publicado: (2023)

Nonerythropoietic Erythropoietin Mimetic Peptide ARA290 Ameliorates Chronic Stress-Induced Depression-Like Behavior and Inflammation in Mice
por: Xu, Guanglei, et al.
Publicado: (2022)

Physician consultation rates and characteristics among workers with chronic pain or headache who participated in a behavioural change program: a retrospective database analysis using real-world healthcare data
por: Nozawa, Kazutaka, et al.
Publicado: (2022)

Pomegranate Peel Extract Decreases Plaque Necrosis and Advanced Atherosclerosis Progression in Apoe ( -/- ) Mice
por: Manickam, Vijayprakash, et al.
Publicado: (2022)

Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib
por: Lecis, D, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_es3dbvdsfpg0qm6dsa5k2dns79